eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | tuberous sclerosis |
| Symptom | C0206633|angiomyolipoma |
| Sentences | 18 |
| PubMedID- 24729041 | The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, phase 3 trial exist-1. |
| PubMedID- 23312829 | Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (exist-2): a multicentre, randomised, double-blind, placebo-controlled trial. |
| PubMedID- 24833837 | 2 twenty percent of all renal angiomyolipoma are associated with tuberous sclerosis and they typically present at a younger age (mean age 30 years) with bilateral multifocal angiomyolipoma. |
| PubMedID- 24159414 | But bladder angiomyolipoma associated with tuberous sclerosis has not been seen in the literature. |
| PubMedID- 24777052 | Inhibition of mtor with rapalogs has shown clinical efficacy against some solid tumors, including everolimus for angiomyolipoma associated with tuberous sclerosis, metastatic renal cell carcinoma, breast cancer, or pancreatic neuroendocrine carcinomas and temsirolimus for renal cell carcinoma –. |
| PubMedID- 24522027 | Re: everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (exist-2): a multicentre, randomised, double-blind, placebo-controlled trial. |
| PubMedID- 25884947 | Rapamycin belongs to the class of macrocyclic immunosuppressive drugs used in preventing rejection after organ transplantation, topical treatment of facial angiofibromas, renal angiomyolipoma, brain tumors associated with tuberous sclerosis and chemotherapy for a variety of cancers. |
| PubMedID- 26156073 | Background: mammalian target of rapamycin (mtor) inhibitors are recommended as first-line treatment of renal angiomyolipoma associated with tuberous sclerosis complex (tsc) or sporadic lymphangioleiomyomatosis (sporadic lam), but follow-up is limited. |
| PubMedID- 23689226 | Additional oncology indications for everolimus include renal angiomyolipoma with tuberous sclerosis complex and subependymal giant-cell astrocytoma. |
| PubMedID- 23312828 | Everolimus for renal angiomyolipoma in tuberous sclerosis. |
| PubMedID- 23642941 | Commentary on: everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (exist-2): a multicentre, randomised, double-blind, placebo-controlled trial. |
| PubMedID- 23054313 | Purpose: renal angiomyolipoma in patients with tuberous sclerosis can cause life-threatening bleeding. |
| PubMedID- 24813310 | Efficacy and safety of sirolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: a systematic review. |
| PubMedID- 26279726 | Composite renal cell carcinoma and angiomyolipoma in a patient with tuberous sclerosis: a diagnostic dilemma. |
| PubMedID- 25580845 | Renal epithelioid angiomyolipoma in a patient with tuberous sclerosis. |
| PubMedID- 24640214 | Bilateral renal angiomyolipoma in tuberous sclerosis is a rare entity. |
| PubMedID- 24170533 | Purpose: to describe the role of mammalian target of rapamycin (mtor) inhibition in the treatment of tuberous sclerosis complex (tsc) patients with renal angiomyolipoma in relation to available clinical data and clinical practice guidance for the nurse practitioner (np). |
| PubMedID- 20551552 | An unusual case of multifocal renal angiomyolipoma associated with tuberous sclerosis and presenting as massive intra abdominal hemorrhage is reported. |
Page: 1